FDA Grants Priority Review to BridgeBio's Oral Infigratinib for Achondroplasia
BBIO sits 25% above its 52-week low of $52.75.
Summary
BridgeBio's NDA for oral infigratinib in children with achondroplasia was accepted by the FDA with Priority Review and a PDUFA date of February 4, 2027. The filing is supported by Phase 3 data showing the strongest efficacy package reported to date in achondroplasia.
Key Events · Product Development and Regulatory · BBIO
-
FDA Accepts NDA with Priority Review
FDA accepted BridgeBio's NDA for oral infigratinib in children with achondroplasia and granted Priority Review, with a PDUFA target action date of February 4, 2027.
-
Strongest Phase 3 Efficacy Data in Achondroplasia
PROPEL 3 met its primary endpoint with a mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001) and showed the first statistically significant improvements in body proportionality and arm span in an achondroplasia Phase 3 trial.
-
First-in-Class Oral Therapy Potential
If approved, oral infigratinib would be the first and only approved oral therapy for children with achondroplasia, with BridgeBio anticipating U.S. launch upon approval.
-
Regulatory Timeline
PDUFA target action date is February 4, 2027. BridgeBio also plans to submit a Marketing Authorization Application to the EMA in Q4 2026.
Analysis · BBIO · Life Sciences
The FDA accepted BridgeBio's NDA for oral infigratinib in children with achondroplasia and granted Priority Review, setting a PDUFA date of February 4, 2027. This is a major regulatory milestone for a potential first-in-class oral therapy. The PROPEL 3 data supporting the filing showed the largest annualized height velocity treatment effect of any Phase 3 study in achondroplasia (+2.10 cm/yr; p<0.0001) and the first statistically significant improvements in body proportionality and arm span. If approved, infigratinib would be the first and only oral therapy for this indication, positioning BridgeBio for a U.S. launch upon approval. The Priority Review designation reflects the FDA's recognition of significant unmet need, and the February 2027 PDUFA date gives investors a concrete near-term catalyst.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $65.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $52.75 to $93.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.